NSAID Labeling Revisions Revised By FDA; Compliance Date Extended
This article was originally published in The Tan Sheet
Executive Summary
FDA has deleted the part of its recommended heart risk warning for NSAIDs that discourages use for "longer than 10 days or more than the recommended dose.
You may also be interested in...
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen